AMRN/OMTH—Are you suggesting Epanova is a serious competitor to Vascepa?
No, not at all. Rather, I was suggesting that the OMTH IPO may have gotten off to a bad start because investors are aware that AMRN has been a poor investment during the past year or so.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.